Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Ophthalmic Genet ; 41(4): 397-400, 2020 08.
Article in English | MEDLINE | ID: mdl-32490703

ABSTRACT

BACKGROUND: . Intravitreal administration of topotecan shows activity against tumor vitreous seeding in the conservative treatment of retinoblastoma, a malignant tumor originated in the retina of small children. Adequate storage of the intravitreal topotecan solution would allow immediate availability for patients at health care institutions. The goal of the work was to address the stability of the intravitreal topotecan formulation upon reconstitution. MATERIALS AND METHODS: . Intravitreal topotecan solutions were reconstituted (at a concentration of 0.2 mg topotecan in 1 mL saline solution vehicle, aliquoted in 1 mL plastic syringes) and stored either frozen or at room temperature for different times. Topotecan content was analyzed at time zero and at different conditions using a high performance liquid chromatography method to quantify topotecan lactone (active) and to detect its pH-dependent hydrolysis product, the open carboxylate. RESULTS: . We found that intravitreal topotecan syringes remained stable at room temperature at least for 24 h, at least for 167 days upon stored frozen at -20°C, and up to 8 h after thawing at day 6. The degradation carboxylate product did not appear in the analyzed thawed samples during the whole study. CONCLUSIONS: . This study confirms the stability of frozen intravitreal topotecan syringes and will help optimize the use of this chemotherapy modality at institutions with low resources. Storage of aliquots will also help reduce personnel exposure to chemotherapy at hospital pharmacies.


Subject(s)
Drug Stability , Drug Storage/standards , Topoisomerase I Inhibitors/chemistry , Topoisomerase I Inhibitors/metabolism , Topotecan/chemistry , Topotecan/metabolism , Humans , Intravitreal Injections , Topoisomerase I Inhibitors/analysis , Topotecan/analysis
2.
Sci Rep ; 10(1): 8766, 2020 05 29.
Article in English | MEDLINE | ID: mdl-32472017

ABSTRACT

We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and evaluated enhanced delivery of irinotecan chemotherapy to the brain and a rat glioma model. Animals received three weekly sessions of FUS, FUS and 10 mg/kg irinotecan, or irinotecan alone. In each session, four volumetric sonications targeted 36 locations in one hemisphere. With feedback control based on recordings of acoustic emissions, 98% of the sonication targets (1045/1071) reached a pre-defined level of acoustic emission, while the probability of wideband emission (a signature for inertial cavitation) was than 1%. BBB disruption, evaluated by mapping the R1 relaxation rate after administration of an MRI contrast agent, was significantly higher in the sonicated hemisphere (P < 0.01). Histological evaluation found minimal tissue effects. Irinotecan concentrations in the brain were significantly higher (P < 0.001) with BBB disruption, but SN-38 was only detected in <50% of the samples and only with an excessive irinotecan dose. Irinotecan with BBB disruption did not impede tumor growth or increase survival. Overall these results demonstrate safe and controlled BBB disruption with a low-frequency clinical TcMRgFUS device. While irinotecan delivery to the brain was not neurotoxic, it did not improve outcomes in the F98 glioma model.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Blood-Brain Barrier , Irinotecan/pharmacokinetics , Magnetic Resonance Imaging/methods , Sonication/methods , Topoisomerase I Inhibitors/pharmacokinetics , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/analysis , Antineoplastic Agents/therapeutic use , Brain Edema/etiology , Brain Neoplasms/drug therapy , Female , Glioma/drug therapy , Irinotecan/administration & dosage , Irinotecan/analysis , Irinotecan/therapeutic use , Male , Microbubbles , Pilot Projects , Prodrugs/administration & dosage , Prodrugs/analysis , Prodrugs/pharmacokinetics , Prodrugs/therapeutic use , Purpura/etiology , Random Allocation , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley , Sonication/adverse effects , Sonication/instrumentation , Topoisomerase I Inhibitors/administration & dosage , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/therapeutic use
3.
AAPS PharmSciTech ; 20(3): 133, 2019 Feb 28.
Article in English | MEDLINE | ID: mdl-30820689

ABSTRACT

Irinotecan (IRT), the pro-drug of SN-38, has exhibited potent cytotoxicity against various tumors. In order to enhance the anti-tumor effect of IRT, we prepared IRT-loaded PLGA nanoparticles (IRT-PLGA-NPs) by emulsion-solvent evaporation method. Firstly, IRT-PLGA-NPs were characterized through drug loading (DL), entrapment efficiency (EE), particle size, zeta potential, transmission electron microscopy (TEM), and differential scanning calorimetry (DSC). We next studied the in vitro release characteristics of IRT-PLGA-NPs. Finally, the pharmacokinetics and pharmacodynamics profiles of IRT-PLGA-NPs were investigated. The results revealed that IRT-PLGA-NPs were spherical with an average size of (169.97 ± 6.29) nm and its EE and DL were (52.22 ± 2.41)% and (4.75 ± 0.22)%, respectively. IRT-PLGA-NPs could continuously release drug for 14 days in vitro. In pharmacokinetics studies, for pro-drug IRT, the t1/2ß of IRT-PLGA-NPs was extended from 0.483 to 3.327 h compared with irinotecan solution (IRT-Sol), and for its active metabolite SN-38, the t1/2ß was extended from 1.889 to 4.811 h, which indicated that IRT-PLGA-NPs could prolong the retention times of both IRT and SN-38. The pharmacodynamics results revealed that the tumor doubling time, growth inhibition rate, and specific growth rate of IRT-PLGA-NPs were 2.13-, 1.30-, and 0.47-fold those of IRT-Sol, respectively, which demonstrated that IRT-PLGA-NPs could significantly inhibit the growth of tumor. In summary, IRT-PLGA-NPs, which exhibited excellent therapeutic effect against tumors, might be used as a potential carrier for tumor treatment in clinic.


Subject(s)
Antineoplastic Agents/chemical synthesis , Irinotecan/chemical synthesis , Nanoparticles/chemistry , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer/chemical synthesis , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/analysis , Biocompatible Materials/administration & dosage , Biocompatible Materials/analysis , Biocompatible Materials/chemical synthesis , Calorimetry, Differential Scanning/methods , Cell Line, Tumor , Drug Carriers/administration & dosage , Drug Carriers/analysis , Drug Carriers/chemical synthesis , Drug Evaluation, Preclinical/methods , Irinotecan/administration & dosage , Irinotecan/analysis , Mice , Nanoparticles/administration & dosage , Nanoparticles/analysis , Polylactic Acid-Polyglycolic Acid Copolymer/administration & dosage , Polylactic Acid-Polyglycolic Acid Copolymer/analysis , Topoisomerase I Inhibitors/administration & dosage , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/chemical synthesis , Tumor Burden/drug effects , Tumor Burden/physiology
4.
Anal Bioanal Chem ; 410(15): 3587-3595, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29476234

ABSTRACT

Rhamnus davurica Pall. (R. davurica) has been used as a traditional medicine for many years in China and abroad and shown a wide spectrum of biological activities. Previously, we reported the phytochemical fingerprinting profile of R. davurica, its distinct anti-proliferative activities against HT-29 and SGC-7901 cell lines, and the topoisomerase I (Top I) ligands based on bio-affinity ultrafiltration and HPLC-MS (UF-HPLC-MS). Nevertheless, among the 32 peaks detected in the fingerprinting profile, the common bioactive constituents responsible for the anti-inflammatory and anti-proliferative activities in the extracts remain elusive. To further explore the specific responsible components for their diversified activities and their potential action targets/mechanisms, the method based on bio-affinity UF-HPLC-MS using therapeutic targets like Top I and cyclooxygenase 2 (COX-2) was established to rapidly screen and identify the ligands binding to these known target enzymes. As a result, 12 components were revealed as potential Top I ligands along with 11 components as potential COX-2 ligands, where several components were revealed to possess both activities. Further validations of these bioactive components have also been conducted and confirmed their highlighted activities. This integrated method of UF-HPLC-MS exhibits high efficiency in rapidly screening for multi-target bioactive components responsible for multiple pharmacological effects from the complex natural products and could be very useful to explain the complex action mechanisms of herb medicines in a complex multi-component and multi-target mode at the molecular level. Graphical abstract Schematic diagram of UF-HPLC-MS assay to screen for Top I and COX-2 ligands. The principle of the assay usually involves the following steps: incubation, ultrafiltration, and identification.


Subject(s)
Anti-Inflammatory Agents/analysis , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/analysis , Antineoplastic Agents/pharmacology , Cell Proliferation/drug effects , Rhamnus/chemistry , Anti-Inflammatory Agents/isolation & purification , Antineoplastic Agents/isolation & purification , Cell Line, Tumor , Chromatography, High Pressure Liquid/methods , Cyclooxygenase 2/metabolism , Cyclooxygenase 2 Inhibitors/analysis , Cyclooxygenase 2 Inhibitors/isolation & purification , Cyclooxygenase 2 Inhibitors/pharmacology , DNA Topoisomerases, Type I/metabolism , Drug Discovery , Flavonoids/analysis , Flavonoids/isolation & purification , Flavonoids/pharmacology , Humans , Neoplasms/drug therapy , Spectrometry, Mass, Electrospray Ionization/methods , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/isolation & purification , Topoisomerase I Inhibitors/pharmacology , Ultrafiltration/methods
5.
Spectrochim Acta A Mol Biomol Spectrosc ; 180: 234-241, 2017 Jun 05.
Article in English | MEDLINE | ID: mdl-28315620

ABSTRACT

This paper describes the synthesis of a novel series of acridine thiosemicarbazones through a two-step reaction between various isothiocyanates and hydrazine followed by treatment with acridin-9-carbaldehyde. The properties of this series of seven new derivatives are studied using NMR and biochemical techniques, and the DNA-binding properties of the compounds are determined using spectrophotometric studies (UV-vis absorption, fluorescence, and circular/linear dichroism) and viscometry. The binding constants K are estimated as being in the range of 2.2 to 7.8×104M-1 and the percentage of hypochromism was found to be 22.11-49.75% (from UV-vis spectral titration). Electrophoretic experiments prove that the novel compounds demonstrate moderate inhibitory effects against Topo I activity at a concentration of 60×10-6M.


Subject(s)
Acridines , Thiourea , Topoisomerase I Inhibitors , Acridines/analysis , Acridines/chemistry , Acridines/metabolism , Circular Dichroism , DNA/chemistry , DNA/metabolism , DNA Topoisomerases, Type I , Magnetic Resonance Spectroscopy , Models, Molecular , Spectrophotometry, Ultraviolet , Thiosemicarbazones/analysis , Thiosemicarbazones/chemistry , Thiosemicarbazones/metabolism , Thiourea/analysis , Thiourea/chemistry , Thiourea/metabolism , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/chemistry , Topoisomerase I Inhibitors/metabolism
6.
Chem Pharm Bull (Tokyo) ; 64(7): 947-51, 2016.
Article in English | MEDLINE | ID: mdl-27373651

ABSTRACT

Non-reducing iterative type I polyketide synthase genes, pnk1 and pnk2, were cloned from the fungus Phoma sp. BAUA2861, which produces the topoisomerase I inhibitors, topopyrones A to D. Heterologous expression of these polyketide synthase genes under the α-amylase promoter in Aspergillus oryzae was carried out to identify their functions. The pnk2 transformant produced topopyrones C, D, and haematommone. Therefore, the pnk2 gene was found to encode for the topopyrone nonaketide synthase.


Subject(s)
Ascomycota/enzymology , Polyketide Synthases/metabolism , Topoisomerase I Inhibitors/analysis , Anthraquinones/analysis , Anthraquinones/metabolism , DNA Topoisomerases, Type I/metabolism , Humans , Molecular Structure , Polyketide Synthases/genetics , Pyrones/analysis , Pyrones/metabolism , Topoisomerase I Inhibitors/metabolism
7.
Arch Toxicol ; 90(11): 2809-2823, 2016 Nov.
Article in English | MEDLINE | ID: mdl-26542539

ABSTRACT

Methyleugenol is a substituted alkenylbenzene found in several herbs and spices. It is classified by the European Union's Scientific Committee on Food as a genotoxic carcinogen. We addressed the biological mechanism of the genotoxic properties of methyleugenol and its oxidative metabolites. Methyleugenol and the oxidative metabolites significantly enhanced the DNA damage in human colon carcinoma cells (HT29). Methyleugenol did not affect the protein status of γH2AX, a biomarker of DNA double-strand breaks, whereas its metabolites methyleugenol-2',3'-epoxide and 3'-oxomethylisoeugenol significantly increased the cellular phosphorylated H2AX level. Both of these metabolites also showed a significant induction of micronuclei in HT29 cells. Furthermore, we investigated whether topoisomerase interaction contribute to the observed effect on DNA integrity. Methyleugenol-2',3'-epoxide and 3'-oxomethylisoeugenol inhibited the activity of recombinant topoisomerase I. In HT29 cells, neither methyleugenol nor the metabolites affected the level of topoisomerase protein bound to DNA, excluding a topoisomerase poisoning mode of action. In addition, 3'-oxomethylisoeugenol potently diminished the level of camptothecin-stabilized topoisomerase I/DNA intermediates and camptothecin-induced DNA strand breaks. In conclusion, it could be suggested that 3'-oxomethylisoeugenol may also interact with classical or food-borne topoisomerase I poisons, diminishing their poisoning effectiveness.


Subject(s)
Carcinogens, Environmental/toxicity , Colonic Neoplasms/chemically induced , DNA Damage , DNA Topoisomerases, Type I/metabolism , Eugenol/analogs & derivatives , Mutagens/toxicity , Topoisomerase I Inhibitors/toxicity , Biomarkers, Tumor/agonists , Biomarkers, Tumor/metabolism , Biotransformation , Carcinogens, Environmental/analysis , Carcinogens, Environmental/metabolism , Carcinoma/chemically induced , Carcinoma/enzymology , Colonic Neoplasms/enzymology , Colonic Neoplasms/metabolism , Comet Assay , DNA Topoisomerases, Type I/chemistry , DNA Topoisomerases, Type I/genetics , Epoxy Compounds/analysis , Epoxy Compounds/metabolism , Epoxy Compounds/toxicity , Eugenol/analysis , Eugenol/metabolism , Eugenol/toxicity , Food Contamination , HT29 Cells , Histones/agonists , Histones/metabolism , Humans , Micronucleus Tests , Mutagens/analysis , Mutagens/metabolism , Neoplasm Proteins/agonists , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Oxidation-Reduction , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Spices/adverse effects , Spices/analysis , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/metabolism
8.
Acta Pol Pharm ; 70(3): 451-8, 2013.
Article in English | MEDLINE | ID: mdl-23757936

ABSTRACT

A series of new benzimidazole derivatives with potential anticancer activity were tested as a new topoisomerase I inhibitors. The fluorometric method was used to determine in vitro the quantitative level of plasmid DNA relaxation by these compounds. Optimization of the fluorometric system and validation of the established analytical method were performed. Out of benzimidazole derivatives which were analyzed, in the case of five derivatives inhibition of topoisomerase I was greater than camptothecin (compounds 11, 12, 15, 21, 22).


Subject(s)
Benzimidazoles/chemical synthesis , Fluorometry/methods , Topoisomerase I Inhibitors/chemical synthesis , Benzimidazoles/analysis , Topoisomerase I Inhibitors/analysis
9.
Article in English | MEDLINE | ID: mdl-22660213

ABSTRACT

AIM: To determine intravitreal and plasma concentrations and retinal toxicity after transcorneal intravitreal injection of 1 µg and 2 µg of topotecan (Hycamtin). METHOD: Twelve healthy albino rabbits were included in this in vivo experiment. Six anesthetized albino rabbits received a single transcorneal intravitreal injection of 1 µg (group A) or 2 µg (group B) of topotecan. Vitreous and blood samples were collected until 168 h. Left eyes were treated with the same volume of saline. Plasma and vitreous levels of topotecan were determined by high-performance liquid chromatography. Area under the plasma concentration time curve (AUC) was calculated using trapezoidal rule. Clinical evidence of toxicity was classified into four grades according to anatomical structures. Electroretinograms (ERGs) were recorded. RESULTS: Time to maximum concentration was observed up to 2 h after drug injection in group A whereas up to 1 h in group B. Low levels of topotecan were detected in plasma in both groups and in the vitreous humor of the contralateral eye in group B. Topotecan levels (mean vitreous AUC in group A 2.55 µg/mL.h and in group B 5.338 µg/mL.h) were detectable up to 6 h in both groups. We observed following structural changes in rabbit eyes: corneal vascularization, cataract, hemophthalmus, choroidal edema and focal retinal atrophy. Abnormal ERGs were obtained. CONCLUSION: Our findings proved that transcorneal intravitreal administration of 1 µg and 2 µg of topotecan results in potentially cytotoxic intraocular concentrations. More studies are needed to establish the safety of topotecan for retinoblastoma in children.


Subject(s)
Retina/drug effects , Retinal Neoplasms/drug therapy , Retinoblastoma/drug therapy , Topoisomerase I Inhibitors/administration & dosage , Topotecan/administration & dosage , Vitreous Body/chemistry , Animals , Rabbits , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/blood , Topotecan/analysis , Topotecan/blood
10.
J Pharm Pharm Sci ; 14(2): 138-47, 2011.
Article in English | MEDLINE | ID: mdl-21733405

ABSTRACT

PURPOSE: To determine experimentally the intestinal permeability of the anticancer prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is intestinally excreted (exsorped) as a predictor of intestinal toxicity, and to assess the effect of p-glycoprotein (p-gp) inhibitors (verapamil as a model) on the permeability and toxicity of irinotecan. METHODS: Single pass intestinal perfusion of rat's whole length small intestines is applied to assess the permeability of the parent drug and quantify the intestinally excreted metabolite. The perfusion solution contained 30µg/ml of irinotecan (control group) without or with verapamil (verapamil group). A simple reversed phase HPLC method with UV detection is developed and validated for simultaneous determination of irinotecan and SN-38 using camptothecin as an internal standard. RESULTS: HPLC-UV method found to be simple, specific, accurate, and precise. Effective permeability coefficient of irinotecan found to be 4.9±1.7 10-3 mm/min and was doubled in verapamil group (P=0.007). Average cumulative amount of SN-38 exsorped found to be 29 ng/cm over 2 hours perfusion time which was decreased to 15 ng/cm in verapamil group (P=0.016). CONCLUSIONS: in situ intestinal perfusion method was successfully applied to quantify the permeability of irinotecan and the exsorption of SN-38 in the same experiment, in a manner that robustly reflects real in vivo situation. P-gp inhibition using verapamil found to significantly enhance the intestinal permeability of irinotecan and potentially decrease the intestinal toxicity due to SN-38 exposure.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Camptothecin/analogs & derivatives , Chromatography, High Pressure Liquid/methods , Drug Interactions , Intestinal Absorption/physiology , Intestinal Mucosa/metabolism , Perfusion , ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Animals , Calibration , Camptothecin/administration & dosage , Camptothecin/metabolism , Camptothecin/pharmacokinetics , Drug Stability , Intestinal Absorption/drug effects , Intestines/drug effects , Irinotecan , Male , Rats , Rats, Sprague-Dawley , Topoisomerase I Inhibitors/analysis , Topoisomerase I Inhibitors/chemistry , Topoisomerase I Inhibitors/metabolism , Verapamil/pharmacology
11.
Eur J Pharm Biopharm ; 79(1): 181-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21303693

ABSTRACT

The purpose of this work was to encapsulate 7-Ethyl-10-hydroxy-camptothecin (Sn38) in lipid nanocapsules (LNCs) using phase inversion-based method in order to deliver Sn38 by oral route. LNCs were prepared by a low-energy emulsification method and were characterized for size, polydispersity index (PDI), surface charge, drug payload, in vitro drug release, and storage stability. Moreover, in view of an oral administration, in vitro stability in gastrointestinal fluid and permeability across Caco-2 cells were tested. Sn38-loaded LNCs with a mean particle size of 38±2 nm were obtained. The particles displayed a narrow size distribution and a drug payload of 0.40±0.07 mg/g of LNC dispersion. In vitro stability in simulated gastric and intestinal media was also observed. Finally, Sn38-loaded LNCs improved permeability of Sn38 across Caco-2 cells (5.69±0.87×10(6) cm s(-1) at 6h vs 0.31±0.02×10(6) cm s(-1)) and intracellular concentration compared with free Sn38. In conclusion, Sn38 nanocarriers have been developed and display a strong potential for oral administration.


Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Camptothecin/analogs & derivatives , Drug Delivery Systems , Nanocapsules/chemistry , Topoisomerase I Inhibitors/chemistry , Administration, Oral , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/analysis , Body Fluids/metabolism , Caco-2 Cells , Camptothecin/administration & dosage , Camptothecin/analysis , Camptothecin/chemistry , Drug Compounding , Drug Evaluation, Preclinical , Drug Stability , Electric Conductivity , Excipients/chemistry , Humans , Irinotecan , Lipids/chemistry , Nanocapsules/administration & dosage , Particle Size , Solubility , Topoisomerase I Inhibitors/administration & dosage , Topoisomerase I Inhibitors/analysis , Transendothelial and Transepithelial Migration/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...